A federal jury in San Francisco convicted the founder and the clinical president of the telehealth company Done on November 18, 2025, for distributing more than 40 million pills of Adderall and other stimulants through a subscription model that paid nurse practitioners to refill prescriptions without clinical interaction. Schedule II stimulants such as Adderall and methylphenidate can still be prescribed by telehealth without a prior in-person exam under a temporary DEA extension, not a permanent rule, and the gap between the two is where the Done prosecution took hold. For a telehealth prescriber, a dispensing pharmacy, or a platform operator, the operative question is whether the practice looks like Done's, not whether telehealth prescribing of stimulants is allowed at all.
The Telehealth Flexibility Runs Through December 31, 2026
DEA and HHS published a fourth temporary extension of the COVID-era telemedicine prescribing flexibilities on December 31, 2025, running through December 31, 2026. Under the extension, a DEA-registered practitioner may prescribe Schedule II through V controlled substances by audio-video telemedicine without a prior in-person medical evaluation. A separate proposal, never finalized, would have required Schedule II telehealth prescriptions to carry an in-person referral. That proposal is not law. Under the current extension, Schedule II stimulants carry no referral requirement beyond the general flexibility, which puts the weight of compliance entirely on whether the prescription has a legitimate medical purpose.
The Done Prosecution and What It Signals
The Justice Department's November 19, 2025 announcement confirms convictions in a case DOJ's original charges called its first criminal drug distribution prosecution tied to telemedicine prescribing through a digital health company. The founder and CEO was convicted of conspiracy to distribute controlled substances, four counts of distribution, conspiracy to commit health care fraud, and conspiracy to obstruct justice; the clinical president was convicted on the same distribution and fraud conspiracy counts. These are criminal convictions under the controlled-substances and health care fraud statutes, not a civil False Claims Act case. DOJ's release describes a subscription model built on limited appointment time, auto-refill technology, and payments to nurse practitioners of up to $60,000 per month to keep prescribing stimulants over clinical judgment. The founder and CEO was sentenced on July 7, 2026, to six years in prison and a $1 million fine; the clinical president was sentenced to two years in prison and a $1 million fine. The compensation structure and the prescribing-by-volume pattern the jury convicted on, not the use of telehealth itself, is the exposure every legitimate telehealth prescriber should measure against.
Red Flags That Shape a Pharmacist's Corresponding Responsibility
A pharmacist filling a telehealth stimulant prescription carries the same corresponding responsibility as on any other controlled substance prescription, and cannot treat a valid-looking script as self-verifying. A high volume of Schedule II stimulant prescriptions from a single prescriber with no follow-up visits, and out-of-state patients concentrated around one telehealth platform are the kind of facts a pharmacist cannot ignore once they add up to a high probability that a prescription lacks a legitimate medical purpose. A pharmacy that also distributes to other pharmacies has its own suspicious order monitoring obligation to flag unusual order size, frequency, or pattern before it resupplies, a control separate from the corresponding-responsibility duty owed on an individual script. DEA scrutiny of either duty can escalate to an order to show cause or, in urgent cases, an immediate suspension order against the registration itself.
A prescribing pattern built to maximize volume instead of medical necessity is the exposure, not the use of telehealth itself.
Documentation That Protects a Legitimate Practice
A legitimate telehealth stimulant practice documents the clinical basis for every prescription: a diagnostic history, a reason the encounter occurred by telehealth, and a follow-up plan, not just an initial questionnaire. A dispensing pharmacy's inventory reconciliation for Schedule II stimulants is the record that shows dispensing matches what the pharmacy actually received and ordered, and a discrepancy there is the kind of gap an inspector flags on its own, independent of any individual prescription. A prescriber or pharmacy already facing a DEA inquiry over telehealth stimulant volume should assume the agency will also look at the underlying DEA registration, not only the prescriptions already written.
Why Early Legal Counsel Is Critical
It is critical that telehealth prescribers, dispensing pharmacies, and platform operators promptly retain experienced healthcare defense counsel upon receiving a subpoena, audit notice, or other government inquiry tied to telehealth stimulant prescribing. Early legal intervention can protect the provider's rights, ensure appropriate responses to DEA and DOJ requests, avoid inadvertent admissions, and preserve defenses only available before a registration action or an indictment is filed. Delaying representation can significantly affect the outcome and expose the provider to unnecessary risk.
How Health Law Alliance Can Help
Health Law Alliance's DEA defense attorneys represent telehealth prescribers, dispensing pharmacies, and the distributors behind them, including distributor and reverse distributor registration questions. Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience. If your practice or pharmacy is facing DEA or DOJ scrutiny over telehealth stimulant prescribing, contact Health Law Alliance for a free, confidential consultation.
